A model of tuberculosis screening for pregnant women in resource-limited settings using Xpert MTB/RIF.

J Pregnancy

Tuberculosis Department, Centre for Infectious Disease Research in Zambia, 5977 Benakale Road, P.O. Box 34681, Northmead, Lusaka, Zambia; Schools of Medicine and Public Health, University of Alabama at Birmingham, AL 35233, USA.

Published: June 2013

Timely diagnosis and treatment of maternal tuberculosis (TB) is important to reduce morbidity and mortality for both the mother and child, particularly in women who are coinfected with HIV. The World Health Organization (WHO) recommends the integration of TB/HIV screening into antenatal services but available diagnostic tools are slow and insensitive, resulting in delays in treatment initiation. Recently the WHO endorsed Xpert MTB/RIF, a highly sensitive, real-time PCR assay for Mycobacterium tuberculosis that simultaneously detects rifampicin resistance directly from sputum and provides results within 100 minutes. We propose a model for same-day TB screening and diagnosis of all pregnant women at antenatal care using Xpert MTB/RIF. Pilot studies are urgently required to evaluate strategies for the integration of TB screening into antenatal clinics using new diagnostic technologies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189576PMC
http://dx.doi.org/10.1155/2012/565049DOI Listing

Publication Analysis

Top Keywords

xpert mtb/rif
12
pregnant women
8
screening antenatal
8
model tuberculosis
4
screening
4
tuberculosis screening
4
screening pregnant
4
women resource-limited
4
resource-limited settings
4
settings xpert
4

Similar Publications

Background: Early and accurate diagnosis of drug resistance, including resistance to second-line anti-tuberculosis (TB) drugs, is crucial for the effective control and management of pre-extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB). The Xpert MTB/XDR assay is the WHO recommended method for detecting resistance to isoniazid and second-line anti-TB drugs when rifampicin resistance is detected. Currently, the Xpert MTB/XDR assay is not yet implemented in Ethiopia, thus the MTBDRsl assay continues to be used.

View Article and Find Full Text PDF

Clinical application of time-of-flight mass spectrometry nucleic acid detection technology in diagnosis of drug-resistant pulmonary tuberculosis.

Diagn Microbiol Infect Dis

January 2025

Henan Provincial Chest Hospital tuberculosis within Six/Critical Illness Area, Henan Infectious Diseases(TB)Clinical Research Center, Zhengzhou, Henan, 450001, PR China. Electronic address:

Purpose: This study aims to evaluate the clinical diagnostic value of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for tuberculosis and drug-resistant tuberculosis.

Patients And Methods: Totally 201 pulmonary tuberculosis patients were recruited retrospectively. All patients underwent smear microscopy, Mycobacterium growth indicator tube (MGIT) 960 culture, loop-mediated isothermal amplification (LAMP) molecular testing, Xpert MTB/RIF (Xpert), and MassARRAY assay which is a MALDI-TOF MS based method.

View Article and Find Full Text PDF

Background: Tuberculosis (TB) is a leading cause of death worldwide with over 90% of reported cases occurring in low- and middle-income countries (LMICs). Pre-treatment loss to follow-up (PTLFU) is a key contributor to TB mortality and infection transmission.

Objectives: We performed a scoping review to map available evidence on interventions to reduce PTLFU in adults with pulmonary TB, identify gaps in existing knowledge, and develop a conceptual framework to guide intervention implementation.

View Article and Find Full Text PDF

Background: Targeted next-generation sequencing (tNGS) is promising alternative to phenotypic drug susceptibility testing (pDST) for detecting drug-resistant tuberculosis (DRTB). This study explored the potential cost-effectiveness of tNGS for the diagnosis of DR-TB across 3 settings: India, South Africa and Georgia.

Methods: To inform WHO guideline development group (GDG) on tNGS we developed a stochastic decision analysis model and assessed cost-effectiveness of tNGS for DST among rifampicin resistance individuals.

View Article and Find Full Text PDF

Background: Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative bacteriological test result. There is limited information on the factors that determine clinicians' decisions to initiate TB treatment when initial bacteriological test results are negative.

Methods And Findings: We performed a systematic review and individual patient data meta-analysis using studies conducted between January 2010 and December 2022 (PROSPERO: CRD42022287613).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!